Latest Headlines
- Gore Expands Leadership In Membrane Chromatography With Next-Generation Affinity Solutions 3/31/2026
-
Lonza Launches Media Development Lab In Singapore For Cell Culture Media Optimization
3/26/2026
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of its Media Development Lab at its Singapore site.
-
UCB Announces New Biologics Manufacturing Facility Investment In Georgia
3/25/2026
The State of Georgia, Gwinnett County and the Rowen Foundation today announced that global biopharmaceutical company UCB has selected Rowen as the site of its new U.S. biologics manufacturing campus. The planned project represents a direct investment of approximately $2 billion and is expected to create more than 330 high-quality jobs as the facility comes online over the next several years.
-
Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates
3/19/2026
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announces the launch of its RNA Edge System, an integrated AI, synthetic biology, and laboratory platform to optimize RNA therapies.
-
Abzena Recognized As A Market-Leading Antibody-Drug Conjugate CDMO In Frost & Sullivan Radar Report
3/18/2026
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the Frost Radar™ Report for Antibody Drug Conjugate Contract Development and Manufacturing Organizations.
-
CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry
3/17/2026
Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.
-
BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs
3/16/2026
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.
-
BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market
3/16/2026
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.
- Emerson Streamlines Life Sciences Recipe Creation For Faster Time To Market 3/9/2026
-
LOTTE BIOLOGICS Signs Letter Of Intent (LOI) For Strategic Collaboration With U.S.-Based Multinational Company That Has Also Presence And Operation In Japan And Taiwan
3/6/2026
LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Letter of Intent (LOI) for strategic business collaboration with a multinational biotechnology company headquartered in the United States.